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ABSTRACT
Background: Etanercept binds soluble tumor necrosis factor-alpha (TNF-α) and is classified as pregnancy risk category B. 
Increase in TNF-α level causes preterm labour or miscarriage. Lipopolysaccharides trigger preterm birth and abortion via 
producing of pro-inflammatory cytokines. Cytokines are divided into two groups as pro-inflammatory and anti-inflammatory. 
TNF-α is a pro-inflammatory cytokine, whereas interleukin (IL)-10 is an anti-inflammatory cytokine. IL-10 predominant 
in normal pregnancy while TNF-α characterize in abortion and recurrent abortion. The aim of this study was to determine 
the effect of etanercept on the development of offspring and lipopolysaccharide-induced pregnancy loss.
Materials, Methods & Results: Twenty-eight female and 7 male Wistar rats (5-6 months old) were used in this study. 
The rats were fed a standard pelleted diet and tap water ad libitum. After female rats were caged with males for 1 day, the 
presence of a vaginal plug was designated as day 0 of pregnancy. Twenty-eight pregnant Wistar rats were divided into 4 
equal groups, as follows: control (0.3 mL of Normal Saline Solution intravenously on day 10 of pregnancy); etanercept (0.8 
mg kg-1/day intraperitoneally on days 9 and 10 of pregnancy); lipopolysaccharide (160 µg kg-1 intravenously on day 10 of 
pregnancy); and etanercept + lipopolysaccharide. Blood samples were obtained from the tail vein on day 10 of pregnancy 
(3 h after lipopolysaccharide administration). All animals were followed during pregnancy. Pregnancy rates and offspring 
characteristics were determined. TNF-α and IL-10 levels were measured using an ELISA reader. Etanercept alone did not 
have any negative effects, and etanercept did not prevent (P < 0.05) lipopolysaccharide-induced pregnancy loss. Higher 
TNF-α and IL-10 levels were measured (P < 0.05) in the etanercept + lipopolysaccharide group compared to other groups. 
Discussion: It is well known that use of etanercept does not increase pregnacy loss. In this study, higher pregnancy rates 
were determined in the control and etanercept groups than the lipopolysaccharide and etanercept + lipopolysaccharide 
groups. The proportion of fetal deaths in lipopolysaccharide administered pregnant subjects was decreased by the use of 
anti-TNF-α agents. While the concentrations of TNF-α are low in the onset of pregnancy period, the concentrations of TNF-α 
increases a peak level during the onset of labour. Embryonic resorption is affected by Th1 cytokines (TNF-α and lL-2) and 
low-dose lipopolysaccharide without any affecting mother survival, and in the early pregnancy term, the implantation area 
of embryo is enormously sensitive to these molecules. In the current study, etanercept increased the concentration of TNF-α 
and the concentration of IL-10 when compared to the lipopolysaccharide group. IL-10 has a protective role, while TNF-α 
is an abortive factor during pregnancy. Thus, etanercept did not prevent pregnancy loss. This finding may have reflected an 
insufficient dose of etanercept. Adverse effects did not occur in the offspring of the etanercept or control groups, and there 
was no difference between the two groups statistically. Adverse pregnancy outcomes such as stillbirth, low birth weight, 
spontaneous abortion and herediter malformations are not associated with TNF-α inhibitors. In conclusion, etanercept 
does not pose a major teratogenic risk and has no preventive effects with respect to infection-dependent pregnancy loss.
Keywords: Anti-TNF-α, pregnancy loss, cytokine, offspring.
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INTRODUCTION
Anti- tumor necrosis factor (anti-TNF) drugs 
block the functioning of TNF-α and are used for the 
treatment of immune-mediated diseases, such as pso-
riasis and rheumatoid arthritis [15,21]. TNF-α recep-
tors have a pivotal role in pregnancy and the effects 
of TNF-α are neutralized by soluble forms of TNF-α 
receptors [3]. 
Pregnancy is a complex process and leads to 
activation of the maternal cellular and humoral immune 
system [2,20]. The maternal immune system identifies 
or refuses fetal antigens [27]. The rate of spontaneous 
abortion is 15-20%, with unfavorable outcomes occur-
ring during the first trimester of pregnancy [9]. 
Lipopolysaccharides (LPS) are derived from 
the cell wall of gram-negative bacteria. Because LPS 
triggers preterm birth and abortion via pro-inflammatory 
cytokines, LPS is used in experimental studies involving 
pregnancy [7,17,23]. Cytokines have an important role in 
the reproductive immune response and are divided into 
two groups (pro-inflammatory and anti-inflammatory) 
[3,13]. TNF-α (a pro-inflammatory cytokine) is a T-
helper (Th) 1 cytokine, whereas interleukin (IL)-10 (an 
anti-inflammatory cytokine) is a Th2 cytokine [3,18]. 
Normal pregnancy is characterized by the predominant 
production of T-helper (Th) 2 cytokines, while abortion 
and recurrent abortion is characterized by the predomi-
nant production of Th1 cytokines [6]. 
Since high TNF-α level occurs in pregnancy 
loss, it has been hypothesized that etanercept, an anti-
TNF-α drug, may prevent LPS-induced pregnancy loss.
The aim of this study was to determine the ef-
fect of etanercept on LPS-induced pregnancy loss in 
rats and the development of offspring. 
MATERIALS AND METHODS
Animals
Twenty-eight female and 7 male Wistar rats 
(5-6 months old) were used in this study. The rats were 
fed a standard pelleted diet and tap water ad libitum. 
The animals were bred in standard cages on a 12-h 
light/dark cycle at room temperature in a humidity-
controlled environment. 
Experimental procedure
LPS1 (Escherichia coli, serotype O111:B4) and 
etanercept (Enbrel® flk)2 were diluted with pyrogen-
free saline to the appropriate concentrations. 
After female rats were caged with males for 1 
day, the presence of a vaginal plug was designated as 
day 0 of pregnancy. The 10-12th days of a rat pregnancy 
corresponds roughly to the first trimester of human preg-
nancy [24]. Pregnant rats were randomly divided into 
4 groups, as follows: control group, 0.3 mL of normal 
saline solution was administered intravenously on day 
10 of pregnancy (n = 7); etanercept group, etanercept 
was administered intraperitoneally at 0.8 mg kg-1 day on 
days 9 and 10 of pregnancy (n = 7); LPS group, LPS was 
administered intravenously via the tail vein at 160 µg kg-1 
on day 10 of pregnancy (n = 7); and the etanercept + LPS 
group, etanercept was administered intraperitoneally at 
0.8 mg kg-1 day on days 9 and 10 of pregnancy + LPS 
was administered intravenously at 160 µg kg-1 on day 10 
of pregnancy (n = 7). Blood samples were obtained from 
the tail vein on day 10 of the experiment (3 h after LPS 
administration) and all animals were followed during 
pregnancy. Animals that did and did not give birth were 
determined. In addition, the development of offspring was 
assessed. At the conclusion of the study, all animals were 
euthanized under thiopental sodium anaesthesia (Pental® 
sodium 1 g)3 [70 mg kg-1, intraperitoneally]. 
Measurements
Blood samples were centrifuged and serum 
samples were stored at -70°C until analysis. TNF-α4 
(rat TNF-α kit, sensitivity 11 pg mL-1) and IL-104 (rat 
IL-10 kit, sensitivity 1.5 pg mL-1) levels were deter-
mined at 450 nm by commercial ELISA kits an with 
ELISA reader (MWGt Lambda Scan 200)5. 
Development of offspring
The weight and body length of the offspring 
were determined with a scale and digital calipers, 
respectively. 
Statistical analysis
The pregnancy rates of the groups were evalu-
ated using a chi-square test. The concentrations of 
TNF-α and IL-10 and the number of offspring in each 
group was compared with ANOVA and a Duncan test 
as a post-hoc test. The weights and lengths of the off-
spring in the control, etanercept, and etanercept + LPS 
groups were evaluated by ANOVA and the Duncan test 
on the first day, while the same data from the control 
and etanercept groups were evaluated by independent 
t-tests on days 8, 15, and 22 because only 2 groups 
remained (SPSS 19.0). Data are expressed as the mean 
± SE. Significance was accepted at the P < 0.05 level. 
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RESULTS
The pregnancy rates of the groups are shown in 
Table 1, and TNF-α and IL-10 levels are presented in 
Table 2. All animals were followed during pregnancy 
and 22 days after birth. Etanercept did not inhibit (P < 
0.05) LPS-induced pregnancy loss, and did not exhibit 
adverse effects on the pregnancy rate (Table 1). The 
TNF-α and IL-10 levels were higher (P < 0.05) in the 
etanercept + LPS group compared to the other groups. 
Although the TNF-α level was not determined in the 
etanercept and control groups, the IL-10 level was 
lower (P < 0.05) in the etanercept and control groups 
(Table 2). The weights and lengths of the offspring on 
days 1, 8, 15, and 22 are shown in Table 3. Adverse 
effects did not occur during the development of off-
spring born from rats in the etanercept alone and con-
trol groups. The number of offspring was statistically 
significant (P < 0.05) in the LPS and etanercept + LPS 
groups when compared to the control and etanercept 
groups (Figure 1).
Table 1. Pregnancy rates of groups.




Etanercept + LPS 7/6b 1
LPS: lipopolysaccharide (160 µg kg-1 intravenously, Escherichia coli 0111:B4). a,bDifferent letters in the same column are statistically 
significant (P < 0.05).
Table 2. TNFα and IL-10 levels of groups.
Group TNFα (pg/mL) IL-10 (pg/mL)
Control ND 294 ± 44.3c
Etanercept ND 206 ± 17.4c
LPS 101 ± 17.3b 798 ± 115b
Etanercept + LPS 1474 ± 358a 1817 ± 174a
TNFα: tumor necrosis factor α; IL-10: interleukin-10; LPS: lipopolysaccharide (160 µg kg-1 intravenously, Escherichia coli 0111:B4). 
ND: not determined. a,b,cDifferent letters in the same column are statistically significant (P < 0.05).
Table 3. Parameters of offspring in groups.
Day 1 Day 8 Day 15 Day 22
Group Weight Length Weight Length Weight Length Weight Length 
Control 7.39 ± 0.10a 51.7 ± 0.29a 13.3 ± 0.21 65.2 ± 0.38a 23.7 ± 0.72b 78.2 ± 0.86 34.9 ± 1.04b 91.0 ± 1.14a
Etanercept 7.05±0.13a 50.8±0.28ab 13.6±0.32 63.5±0.42b 25.5±0.49a 76.2±0.60 39.7±0.84a 86.2±0.56b
Etanercept + 
LPS 5.98 ± 0.17
b 50.1±0.45b MD MD MD MD MD MD
LPS NL NL NL NL NL NL NL NL
MD: Maternal death; NL: No labour; LPS: lipopolysaccharide (160 µg kg-1 intravenously, Escherichia coli 0111:B4). a,bDifferent letters in the same 
column are statistically significant (P < 0.05).
Figure 1. The number of offspring in groups. To induce pregnancy loss with LPS, 160 µg kg-1 LPS (Escherichia coli 0111:B4) was administered intra-
venously via the tail vein on day 10 of pregnancy in the LPS group. Etanercept was administered intraperitoneally at 0.8 mg kg-1day on days 9 and 10 of 
pregnancy in the etanercept and etanercept + LPS groups. Blood samples were obtained from the tail vein on day 10 of the experiment and all animals 
were followed during pregnancy. Animals that did and did not give birth were determined. a, b: Different letters are statistically significant (P < 0.05).
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DISCUSSION
Etanercept is a dimeric fusion protein binding 
that only binds soluble tumor necrosis factor-alpha 
(TNF-α) and is classified by the Food and Drug Admin-
istration as pregnancy risk category B [8,21]. Pregnancy 
outcomes, such as miscarriage, preterm labour, and 
pre-eclampsia, result from changes in TNF-α and its 
receptors [3]. Spontaneous abortions and pre-eclampsia 
are complications in pregnant women, and these com-
plications result from a change in a Th2-biased to a 
Th1-biased cytokine profile in maternal serum [3,6,28].
The aim of this study was to determine the effect 
of etanercept on cytokine levels and offspring develop-
ment in LPS-induced abortion. Several inflammatory 
molecules play important roles in the mechanism underly-
ing early pregnancy loss. Extreme inflammation results in 
unfavorable outcomes, such as spontaneous abortion and 
fetal resorption [1,14]. Recurrent abortion is classically 
defined as three or more pregnancy losses. This usually 
occurs before 20 weeks gestation. Recently, recurrent 
spontaneous miscarriage has been redefined as the spon-
taneous loss of two or more clinical pregnancies [12,29].
Animal models have been used to elucidate 
pregnancy success [16]. In the current study, etanercept 
alone did not have a negative effect on the pregnancy 
rate and did not prevent LPS-induced abortion (Table 1). 
It has been reported that etanercept, which is classified 
as pregnancy risk category B, can be used in pregnant 
women; TNF-α antagonists have no known embryotoxic 
or teratogenic effects. In addition, there is no evidence that 
there is an associated increased pregnancy loss following 
use of etanercept [25]. In this study, higher pregnancy 
rates were determined in the control and etanercept groups 
than the LPS and etanercept + LPS groups (Table 1). The 
uses of anti-TNF-α agents decrease the proportion of fetal 
deaths in LPS-administered pregnant mice [11].
When TNF-α level increases during pregnancy, 
placental perfusion is inadequate, there is an increase 
in thrombotic events, and placental and fetal hypoxia 
occur [22]. In addition, a higher TNF-α level was mea-
sured in the etanercept + LPS group in the current study 
(Table 2). Cytokines play a pivotal role in the pregnancy 
process [26]. Spontaneous abortion, preterm labour, 
pre-eclampsia, and intrauterine growth restriction are 
adverse pregnancy outcomes in which deregulation of 
cytokine networks can result [4]. While the TNF-α level 
is low in the first trimester of pregnancy, the TNF-α 
level reaches a peak during the onset of labour [25]. 
Low-dose LPS and Th1 cytokines (TNF-α and lL-2) 
induce embryonic resorption without affecting mother 
survival, and the implantation site is extremely sensitive 
to these molecules during early pregnancy [1]. It has 
been reported that TNF-α production in fetal membranes 
is increased by LPS. TNF-α has an important role as 
a cytokine in pregnancy and leads to the induction of 
labour in synergy with other inflammatory cytokines, 
which cause uterine contractions [3,25]. TNF-α has an 
effect on blastocyst implantation, endometrial vascular 
permeability, and uterine deciduation. High serum and 
amniotic fluid levels of TNF-α determine fetal growth 
retardation and the onset of labour. It has been reported 
that recurrent pregnancy loss is closely linked to the 
LPS-increased TNF-α level. The mechanism underlying 
fetoplacental resorption caused by LPS may be based on 
haemorrhage, and necrosis results from a direct effect of 
TNF-α on the placental vasculature [10,25].
In the current study, etanercept increased the con-
centration of TNF-α (14.5-fold) and the concentration of 
IL-10 (2.2-fold) when compared to the LPS group (Table 
2). IL-10 has a protective role, while TNF-α is an abor-
tive factor during pregnancy [5]. Thus, etanercept did not 
prevent pregnancy loss. This finding may have reflected an 
insufficient dose of etanercept. In addition, LPS-induced 
abortions are prevented by IL-10 injections or LPS-induced 
fetal death is decreased by IL-10 injections [22,23].
Adverse effects did not occur in the offspring of the 
etanercept or control groups, and there was no difference 
between the two groups statistically. It has been noted that 
TNF-α inhibitors are not associated with adverse pregnancy 
outcomes, including spontaneous abortion, stillbirth, low 
birth weight, and congenital malformations. Based on a 
study in which cynomolgus monkeys received TNF-α 
inhibitors several hundred times the recommended human 
dose, there was no evidence of teratogenic effects, and 
adverse pregnancy or maternal outcomes in embryo-fetal 
perinatal developmental toxicity studies [19]. 
The decreased pregnancy rate in the etanercept 
+ LPS and LPS groups (Table 1) may reflect the inabil-
ity of etanercept to sufficiently increase the level of IL-
10, thus potentiating the effect of etanercept on TNF-α 
production. In conclusion, etanercept may not prevent 
infection- or endotoxemia-mediated pregnancy loss. 
CONCLUSION
Etanercept does not pose a major teratogenic 
risk and has no preventive effects with respect to 
infection-dependent pregnancy loss. 
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